Common Contracts
3 similar Founding Investor Rights Agreement contracts by Alnylam Pharmaceuticals, Inc., Isis Pharmaceuticals Inc, Regulus Therapeutics Inc.
REGULUS THERAPEUTICS INC. FOUNDING INVESTOR RIGHTS AGREEMENTFounding Investor Rights Agreement • August 17th, 2012 • Regulus Therapeutics Inc. • Pharmaceutical preparations
THIS FOUNDING INVESTOR RIGHTS AGREEMENT (the “Agreement”) is entered into as of the 1st day of January 2009, by and among Regulus Therapeutics Inc., a Delaware corporation (the “Company”) on the one hand, and Isis Pharmaceuticals, Inc., a Delaware Corporation (“Isis”) and Alnylam Pharmaceuticals, Inc., a Delaware corporation (“Alnylam”) who are each holders of the Company’s Series A Preferred Stock (the “Preferred Stock”) on the other hand. Isis and Alnylam may be referred to hereinafter collectively as the “Founding Investors” and each individually as a “Founding Investor”. The Company, Isis and Alnylam may be referred to hereinafter collectively as the “Parties” and each individually as a “Party”.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. REGULUS THERAPEUTICS INC. FOUNDING INVESTOR RIGHTS AGREEMENTFounding Investor Rights Agreement • May 8th, 2009 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations
This Founding Investor Rights Agreement (the “Agreement”) is entered into as of the 1st day of January 2009, by and among Regulus Therapeutics Inc., a Delaware corporation (the “Company”) on the one hand, and Isis Pharmaceuticals, Inc., a Delaware Corporation (“Isis”) and Alnylam Pharmaceuticals, Inc., a Delaware corporation (“Alnylam”) who are each holders of the Company’s Series A Preferred Stock (the “Preferred Stock”) on the other hand. Isis and Alnylam may be referred to hereinafter collectively as the “Founding Investors” and each individually as a “Founding Investor”. The Company, Isis and Alnylam may be referred to hereinafter collectively as the “Parties” and each individually as a “Party”.
REGULUS THERAPEUTICS INC. FOUNDING INVESTOR RIGHTS AGREEMENTFounding Investor Rights Agreement • May 7th, 2009 • Isis Pharmaceuticals Inc • Pharmaceutical preparations
THIS FOUNDING INVESTOR RIGHTS AGREEMENT (the “Agreement”) is entered into as of the 1st day of January 2009, by and among Regulus Therapeutics Inc., a Delaware corporation (the “Company”) on the one hand, and Isis Pharmaceuticals, Inc., a Delaware Corporation (“Isis”) and Alnylam Pharmaceuticals, Inc., a Delaware corporation (“Alnylam”) who are each holders of the Company’s Series A Preferred Stock (the “Preferred Stock”) on the other hand. Isis and Alnylam may be referred to hereinafter collectively as the “Founding Investors” and each individually as a “Founding Investor”. The Company, Isis and Alnylam may be referred to hereinafter collectively as the “Parties” and each individually as a “Party”.
